February 15, 2024
Takeda Pharmaceutical said on February 14 that it has submitted a new drug application for a combination of human immunoglobulin infusion and recombinant human hyaluronidase, known as Hyqvia overseas, for the treatment of agammaglobulinemia and hypogammaglobulinemia. Agammaglobulinemia and hypogammaglobulinemia are...read more